<img src="https://ml-eu.globenewswire.com/Resource/Download/31b5d115-c4a3-4dfd-b20e-d222199c4862?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Zealand Logo (1).png" alt="Zealand Pharma"/>Company announcement – No. 24 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June 10, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&amp;D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at <a href="https://www.globenewswire.com/Tracker?data=qE8OIE63f4mC6JT9rBttcxRAmm68bkV9nd7pBhkSEXfw1vZ6R-Qy3ebyKfpTtBlO9IKL8wKf2IFgUDD7WIE1b2VsUweCFnwfcWpKrUuih7Y=" rel="nofollow" target="_blank" title="www.zealandpharma.com">www.zealandpharma.com</a>. Contacts Eric Rojas (Investors) Vice President, Head of Investor Relations Zealand Pharma Email: erojas@zealandpharma.com Neshat Anis Ahmadi (Investors) Investor Relations Manager Zealand Pharma Email: neahmadi@zealandpharma.com Rachel James-Owens (Media) Vice President, Corporate Communications and Media Relations Zealand Pharma Email: rjamesowens@zealandpharma.com Andreas Hylleberg Mølleskov (Media) Director, External Communications Zealand Pharma Email: ahylleberg@zealandpharma.com 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=X1bFmVgH3akysuNazBQtSzwwG2oN4p4PY3Pa_BVoM6GcTzNJo1xKJByvpBjRYIg70bh5Qaxx5bm8tKDCuJD1oG-y8TaG6MwRmuEYr1we_B_VymeEK3XGMOZt3mEf5EmO-tigjhDcit5TZu4xta0v3e-EWctQTQ4de4_tcKrP2Gf-ZzMVW9hsZZ8FJ2Mjy843" title="10062026 - PDMR transactions" rel="nofollow">10062026 - PDMR transactions</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/ZjlmYjFkMDgtMjAwNi00ZWM0LTk4YmEtMDFiMTU2ZDdiNmFiLTEwMTMyNzQtMjAyNi0wNi0xMC1lbg==/tiny/Zealand-Pharma.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn